Raven and BTI Collaborate in Cancer Stem Cell Discovery
Posted on: Tuesday, 8 April 2008, 12:01 CDT
Raven biotechnologies and the Bioprocessing Technology Institute have announced a collaboration to advance the discovery of novel cancer stem cell antibodies.
Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with Bioprocessing Technology Institute (BTI)'s stem cells. Raven will screen the resulting antibodies against its collection of cancer lines, including its cancer stem cell lines. Raven will have the rights to the antibodies BTI generates using Raven's immunization technology for use in cancer therapeutics and diagnostics and BTI will retain the rights to the antibodies it raises for all other stem cell therapeutic areas.
George Schreiner, CEO of Raven, said: "We anticipate that this collaboration should yield a substantial number of novel monoclonal antibodies targeting cancer stem cells suitable for development by Raven biotechnologies and its partners."
Source: Datamonitor
Related Articles
- Scientists Discover Bladder Cancer Stem Cell
- ImmunoCellular Therapeutics Presents Data Demonstrating Immune Response Targeting Cancer Stem Cells
- ImmunoCellular Therapeutics Announces Filing of Patent Application for a Novel Cancer Stem Cell Vaccine Technology
- ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem Cell Vaccine in Preclinical Model
- Arius's Therapeutic Antibody Inhibits Leukemic Cancer Stem Cells
- Stanford Gets $20M Cancer-Stem Cell Site
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
- OncoMed Pharmaceuticals Granted Fundamental Patent for Identifying Therapeutics Targeting Cancer Stem Cells
- Cancer Stem Cell Found for Tumors
 |
 |
User Comments (0)
RSS Feeds